News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alzheimer's Setback Makes Elan Corporation PLC (ELN) Takeover Bait to Biogen Idec, Inc. (Massachusetts) (BIIB)



7/27/2012 7:57:11 AM

Bad news for Elan Corp. (ELN) (ELN)’s Alzheimer’s drug is turning into good news for Biogen Idec Inc.’s takeover options. Elan sank (ELN) 15 percent, the most since 2009, on July 24 following disappointing results for bapineuzumab, an Alzheimer’s therapy developed with Pfizer Inc. (PFE) (PFE) and Johnson & Johnson. The failure of that drug would leave Elan with a single major product, the multiple sclerosis treatment Tysabri that Biogen co-owns, priming the $7.1 billion company for a deal with Biogen, Jefferies Group Inc. and Royal Bank of Canada said.

Read at BusinessWeek


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES